More radionuclide therapy is better for prostate cancer patients

November 1, 2011 in Cancer

For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

Approximately 50 percent of prostate cancer patients develop that are predominately osteoblastic, that is, have the tendency to fracture resulting in serious morbidity. This type of often leads to chronic pain syndrome in prostate cancer patients; as many as 50 percent of prostate cancer patients with chronic pain syndrome are reported to receive inadequate pain treatment, which makes them candidates for radionuclide therapy.

The retrospective study, "Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A ," reviewed cases of 60 patients with hormone-refractory prostate cancer. The patients, all of whom had more than five lesions documented by a bone scan, were divided into three groups—those who received one therapy, two therapies or three or more therapies.

"Radionuclide therapy of bone metastases has been used for several decades for those with prostate cancer," noted lead author of the study Hans-Juergen Biersack, MD. "For this study, we developed 188Re-HEDP as a novel radiopharmaceutical which—due to it is short half life of 19 hours—makes sequential therapy possible."

The researchers found that post-treatment survival increased with the number of radionuclide therapies administered. Patients with progressive hormone-refractory prostate cancer receiving one therapy added 4.5 months, those receiving two therapies added 10 months, and those receiving three or more therapies improved their survival by 15.7 months. In addition, while the Gleason scores—a grading system used to evaluate the prognosis of men with —for each group were similar, the number of life-lost years for patients receiving three or more therapies was significantly lower.

In regards to pain reduction, no significant difference was found among those receiving 188Re-HEDP therapies. Pain reduction was achieved in 89.5 percent of those receiving one therapy, in 94.7 percent of those receiving two therapies and in 90.9 percent of those receiving three or more therapies.

"For patients failing chemotherapy or hormone treatments, 188Re-HEDP is a promising therapy that can both extend the number of survival years and help relieve pain from bone metastases," noted Biersack. "The findings support and expand the role of molecular therapy with radioisotopes in oncology."

188Re-HEDP is not commercially available and in-house production is required. 188Re-HEDP treatments for this study were developed at Oak Ridge National Laboratory in Oak Ridge, Tenn.

More information: "Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis", Journal of Nuclear Medicine.

Provided by Society of Nuclear Medicine search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

New smartphone application improves colonoscopy preparation

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

Cancer created 20 hours ago | popularity not rated yet | comments 0

Research examines new methods for managing digestive health

Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.

Cancer created 21 hours ago | popularity not rated yet | comments 1

New colonoscope provides ground-breaking view of colon

A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...

Cancer created May 18, 2013 | popularity 5 / 5 (2) | comments 0

ASCO: combo antibody therapy effective for melanoma

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

Cancer created May 17, 2013 | popularity not rated yet | comments 0

Risk factors ID'd for poor cutaneous cell CA outcomes

(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...

Cancer created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast


Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

Ginger compounds may be effective in treating asthma symptoms

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...